Peter Guzzo
Corporate Officer/Principal bei TRYPTAMINE THERAPEUTICS LIMITED
Aktive Positionen von Peter Guzzo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TRYPTAMINE THERAPEUTICS LIMITED | Corporate Officer/Principal | 22.12.2020 | - |
Karriereverlauf von Peter Guzzo
Ehemalige bekannte Positionen von Peter Guzzo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ALBANY MOLECULAR RESEARCH, INC. | Corporate Officer/Principal | 01.01.1996 | 01.01.2015 |
ConSynance Therapeutics, Inc.
ConSynance Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ConSynance Therapeutics, Inc. is an American clinical-stage rare CNS disease company that focuses on Prader-Willi Syndrome (PWS). PWS is a rare genetic disorder that affects approximately 1 in 15,000 people and has no adequate treatment. The hallmark symptom of PWS is an insatiable appetite that causes obesity. The private company was founded by Peter Guzzo, and their focus is on developing treatments for PWS by addressing the dysfunction of the hypothalamus, a small endocrine organ at the base of the brain that plays a crucial role in many bodily functions. | Vorstandsvorsitzender | 01.03.2015 | - |
Gründer | 01.03.2015 | - |
Ausbildung von Peter Guzzo
University of Notre Dame | Doctorate Degree |
Assumption College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Kanada | 2 |
Operativ
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Chief Executive Officer | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Tryp Therapeutics, Inc.
Tryp Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tryp Therapeutics, Inc. is a pharmaceutical company, which engages in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company was founded on September 24, 2019 and is headquartered in Kelowna, Canada. | Health Technology |
ConSynance Therapeutics, Inc.
ConSynance Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ConSynance Therapeutics, Inc. is an American clinical-stage rare CNS disease company that focuses on Prader-Willi Syndrome (PWS). PWS is a rare genetic disorder that affects approximately 1 in 15,000 people and has no adequate treatment. The hallmark symptom of PWS is an insatiable appetite that causes obesity. The private company was founded by Peter Guzzo, and their focus is on developing treatments for PWS by addressing the dysfunction of the hypothalamus, a small endocrine organ at the base of the brain that plays a crucial role in many bodily functions. | Health Technology |
Curia Global, Inc.
Curia Global, Inc. Miscellaneous Commercial ServicesCommercial Services Curia Global, Inc. engages in drug research and development, and manufacturing. It offers drug delivery, drug development, analytical services, API development and manufacturing, and drug product solutions. The company was founded by Thomas E. D'Ambra on June 19, 1991 and is headquartered in Albany, NY. | Commercial Services |
- Börse
- Insiders
- Peter Guzzo
- Erfahrung